Loading clinical trials...
Loading clinical trials...
Phase II Study of Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
Conditions
Interventions
Lorlatinib
Cisplatin or Carboplatin
+1 more
Locations
5
United States
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States
Messino Cancer Center
Asheville, North Carolina, United States
Tennessee Oncology
Nashville, Tennessee, United States
Texas Oncology
Dallas, Texas, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
Start Date
November 1, 2023
Primary Completion Date
March 1, 2025
Completion Date
September 1, 2025
Last Updated
December 13, 2023
NCT06043817
NCT07177937
NCT05671510
NCT06426511
NCT06498635
NCT03563976
Lead Sponsor
SCRI Development Innovations, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions